1. Scrip
  2. >>Business
  3. >>Commercial Strategy

Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.

Expediting
Dyne plans to pursue accelerated approved in both DM1 and DMD • Source: Shutterstock

Dyne Therapeutics has reported new data from Phase I/II studies in myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy that it believes can position each candidate for US accelerated approval with best-in-class potential, and analysts see as validating the Waltham, MA-based company’s platform for oligonucleotide therapeutic.

Key Takeaways

  • Dyne reported new data from ongoing Phase I/II trials of its oligonucleotide conjugate therapies in DM1 and DMD that it thinks offer best-in-class potential.

On 20 May, Dyne reported that DYNE-101, its oligonucleotide antibody-drug conjugate (ADC) therapy for DM1, demonstrated dose-dependent mean splicing correction...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.